Given the close correlation for FGFR1 expression in our in vitro cell model and clinical tumour samples, as well as the specific mode of action for casodex (bicalutmide), we believe that the use of bicalutamide treatment is a valid in vitro tool for modelling androgen ablation. This evidence concerns the gene FGFR1 and neoplasm.